We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A17482
CAS No.
69304-47-8
Formula
C11H13BrN2O5
Mol. Weight
333.14

Documents & Downloads

Brivudine

Cat. No. A17482 CAS 69304-47-8
Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

In Stock

Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 EC50 > 100 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay [PMID: 27032331]
BC-3 IC50 > 15 μM Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay [PMID: 17402726]
C3H EC50 > 100 μg/mL Antiviral activity against MSV in mouse C3H cells assessed as inhibition of virus-induced transformation after 6 days [PMID: 17298047]
CCRF-CEM IC50 > 100 μM Cytostatic activity against human CD4-positive CEM cells after 3 days by cell counting method [PMID: 27818111]
CCRF-CEM EC50 > 50 μM Concentration required to inhibit human immunodeficiency virus-1 (strain ROD) induced cytopathogenicity in CEM cells by 50% [PMID: 16000005]
CCRF-CEM EC50 > 50 μM Concentration required to inhibit human immunodeficiency virus-1 (strain IIIb) induced cytopathogenicity in CEM cells by 50% [PMID: 16000005]
CCRF-CEM IC50 100 μM Cytostatic activity against thymidine kinase deficient human CD4-positive CEM cells after 3 days by cell counting method [PMID: 27818111]
CCRF-CEM CC50 207 μM Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days [PMID: 32515595]
CCRF-HSB-2 IC50 > 100 μg/mL Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay. [PMID: 10206544]
DG-75 IC50 > 15 μM Cytotoxicity against DG75 cells after 120 hrs by MTT assay [PMID: 17402726]
E6SM EC50 > 400 μg/mL Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 0.01 μg/mL Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 16 μg/mL Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
E6SM EC50 80 μg/mL Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture [PMID: 15481985]
HEL IC50 > 100 μg/mL Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. [PMID: 7877148]
HEL IC50 > 100 μg/mL Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. [PMID: 7877148]
HEL CC50 > 100 μM Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter [PMID: 22578783]
HEL EC50 > 100 μM Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days [PMID: 21128666]
HEL EC50 > 100 μM Concentration required to inhibit human cytomegalovirus strain AD169 induced cytopathogenicity in HEL cells by 50% [PMID: 16000005]
HEL EC50 > 100 μM Concentration required to inhibit human cytomegalovirus strain Davis induced cytopathogenicity in HEL cells by 50%

20 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
CAS Number 69304-47-8
Formula C11H13BrN2O5
Molecular Weight 333.14
Synonyms Bromovinyldeoxyuridine; BVDU
SMILES
OC[C@@H]1[C@H](C[C@H](N2C(NC(C(/C=C/Br)=C2)=O)=O)O1)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (180.1 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Added to your cart

View Cart Checkout
Loading...